18/10/2021 - Health

KEY POINTS

·        The economic and social consequences of the Covid-19 pandemic have reiterated the destructive capacity of untreatable infectious diseases.

·        Increased AMR in microbes like bacteria, fungi, and parasites diminish the efficacy of antibiotics in treating simple infections.

·        A recent WHO-supported report has found high rates of AMR in the bloodstream and urinary tracts among the population of countries with reported data on AMR.

·        Apart from the collaboration between governments and multi-lateral agencies, the pharmaceutical sector is a key player for the One Health Approach to have the desired impact.

·        While stabilising the supply chain to absorb future shocks is important, the industry must pivot towards environmentally responsible ways of manufacturing APIs and drugs in finished dosage forms.

·        The government announced a slew of policy measures and incentives for the pharma sector to leverage the industry’s growth potential with incentives for domestic production of APIs and Key Starting Materials (KSMs) and incentivisation of setting up bulk drug parks.

·        In the absence of laws restricting antibiotic residue concentration limits in water bodies, irresponsible production practices continue to drive environmental AMR and weaken the One-Health Approach.

·        The pharmaceutical industry has shaped the lives of millions world over through their medicines, the unsustainable procurement and production practices can offset benefits of these medicines due to increased AMR.

Please review

Pls review

Please Review